Previous 10 | Next 10 |
2018 YTD Chart: +38.68% The benchmark S&P 500 index continues into negative territory for 2018 with over 5% declines this past week. The Momentum Gauges The Momentum Gauge signals continue to maintain higher levels of negative momentum than positive momentum since week 39 (last we...
Lausanne, Switzerland, December 7, 2018 - AC Immune SA (NASDAQ: ACIU), announced today that its Chief Scientific Officer, Dr. Andreas Muhs, passed away following a period of illness. "It is with great sadness that we announce the passing of Dr. Andreas Muhs. Everyone at AC Immune will ...
Update on Therapeutic and Diagnostic Programs Targeting TDP-43 Lausanne, Switzerland, November 1, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases will provide updates on its product...
Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseases Meeting scheduled for November 5, 2018, from 12:00pm - 2:00pm ET AC Immune's Nasdaq Opening Bell ceremony takes place same day at 9:30am ET ...
AC Immune SA (NASDAQ: ACIU ) announces that its partner Life Molecular Imaging (LMI) has presented new clinical study results for 18F-PI-2620, a tau PET-tracer, allowing further extension of tau PET investigations with this compound in therapeutic clinical trials. More news on: AC Immune...
Study confirms the good performance of tau PET-tracer 18 F-PI-2620 in detecting and quantifying tau deposition, a key pathological feature of Alzheimer's disease Results presented at the 11 th Clinical Trials on Alzheimer's Disease Conference (CTAD) in Barcelona, Spain, October 24...
Studies show that crenezumab protects neurons from Alzheimer's disease pathologies in vitro and further support the clinical rationale for crenezumab as a potential treatment for Alzheimer's disease Study on PET eligibility in CREAD Phase 3 showed excellent concordance betw...
Lausanne, Switzerland, October 25, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases has been selected for an oral presentation in the late breaking session at the 11 th annual Clinical ...
2018 YTD Chart: +49.00% Cumulative return with 1-Week holding period. Breakout Forecast Selections for Week 43: The Momentum Gauge conditions continue to worsen over the past several weeks since Week 39. The positive momentum gauge is now down to 7 from a value of 65 at the end of We...
Lausanne, Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Dr. Andreas Muhs, Chief Scientific Officer, will take a medical leave of absence...
News, Short Squeeze, Breakout and More Instantly...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner ...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...